Vistagen Strengthens Its Neurology Focused Pipeline With Pherin Pharma Acquisition

  • Vistagen Therapeutics Inc VTGN has agreed to acquire Pherin Pharmaceuticals Inc in an all-stock transaction of approximately 12.4 million shares.
  • Pherin is a clinical-stage drug development company focused on discovering and developing investigational pherine compounds for neuropsychiatric and neuroendocrine conditions.
  • Related: Independent Biostatisticians Recommend Vistagen Continue Late-Stage Anxiety Trial.
  • Vistagen is gaining full ownership of intellectual property rights to its two most advanced drug candidates, PH94B, currently in Phase 3 development for social anxiety disorder (SAD) and Phase 2 development for adjustment disorder with anxiety (AjDA), and PH10, in clinical development for major depressive disorder (MDD). 
  • Vistagen will also expand its pipeline with three new early clinical-stage pherine product candidates: PH15 for cognition improvement, PH80 for migraine and hot flashes, and PH284 for appetite-related disorders.
  • Price Action: VTGN shares are up 3.13% at $0.11 on the last check Wednesday.
Posted In: BiotechM&ANewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!